← Back to all grants

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Funding
See details
Status
Closing soon
Deadline
September 30, 2026 (18 days left)
Agency
Scope
Nationwide
Source
Grants.gov
Est. $7M total
September 30, 2026 (18 days left)
Nationwide

Description

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.

Eligibility

See official grant page for eligibility requirements

Industry Tags

Healthcare

About This Grant

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.

Funding Information

Estimated Total Program Funding
$7,000,000
Expected Number of Awards
7

Eligibility Overview

This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements.

Federal grant opportunities like this one are typically open to a range of applicant types. Common eligible organizations include:

  • Nonprofits and 501(c)(3) organizations
  • Small businesses and startups (especially for SBIR/STTR programs)
  • State, local, and tribal governments
  • Colleges, universities, and research institutions
  • Individuals (for select programs in education, arts, and research)

Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.

How to Apply

  1. 1

    Review the full opportunity

    Read the complete Notice of Funding Opportunity (NOFO) for this Defense Health Agency Contracting Activity - DHACA program on its official page (https://www.grants.gov/search-results-detail/362194).

  2. 2

    Confirm eligibility

    Check that your organization meets every requirement set by Defense Health Agency Contracting Activity - DHACA — applicant type, location, registration status, and any prior-award restrictions.

  3. 3

    Prepare required documents

    Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.

  4. 4

    Submit before the deadline

    This opportunity closes on September 30, 2026. Submit at least 48 hours early — portal systems are often slow near closing time.

Grant Writing Tips

Proposals for healthcare programs such as those from Defense Health Agency Contracting Activity - DHACA are competitive — these tips can strengthen your application:

  • Start your application at least 4 weeks before the deadline — rushed proposals score lower.
  • Tailor your needs statement to match the funder's stated priorities, using their exact language where possible.
  • Have a colleague outside your team review your budget narrative before submitting — fresh eyes catch errors reviewers penalize.

More Grants from Defense Health Agency Contracting Activity - DHACA

Frequently Asked Questions

Who is eligible for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?

This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements. Always confirm the full eligibility criteria on the official listing before applying.

How much funding does DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award provide?

The total estimated program funding for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award is $7,000,000.

When is the deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?

The application deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award is September 30, 2026. Submit at least 48 hours early to avoid last-minute portal issues.

How do I apply for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?

Apply for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award through the official grant page (https://www.grants.gov/search-results-detail/362194). Confirm your eligibility and prepare your application materials before the deadline.

Helpful Resources

✍️Grant Writing Help

Need help writing your grant application?

Try Instrumentl — Grant Writing Software →
🏢Start Your Business

Need to form an LLC or corporation first?

Form your business with ZenBusiness →
🤝Nonprofit Formation

Starting a nonprofit to apply for grants?

Launch your nonprofit with Swyft Filings →
📊Grant Management

Track and manage multiple grant applications?

Try Bloomerang for nonprofits →

GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.

Related Grants